Trial
NCT03520985
Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Swiss Cancer Institute
Collaborators
—
Condition
Refractory Multiple Myeloma
Intervention
Pomalidomide
Why stopped
Feasibility (low patient accrual and financial reasons)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-06-10